



## NEW INDICATION

As an adjunct to diet, exercise, and standard-of-care therapy in adults with T2D and diabetic nephropathy with albuminuria (>33.9 mg/mmol)

**ONLY INVOKANA<sup>®</sup>**  
**IS INDICATED TO:**



Help reduce the risk of end-stage kidney disease, doubling of serum creatinine, and CV death.

INVOKANA<sup>®</sup> (canagliflozin) is NOW indicated as an adjunct to diet, exercise, and standard-of-care therapy to reduce the risk of ESKD, doubling of serum creatinine, and CV death in adult patients with type 2 diabetes mellitus and diabetic nephropathy with albuminuria (>33.9 mg/mmol).

T2D=type 2 diabetes; CV=cardiovascular; ESKD=end-stage kidney disease.

**Dr. Invokana<sup>®</sup>**  
canagliflozin tablets

Please consult the Product Monograph available at [www.janssen.com/canada/products](http://www.janssen.com/canada/products) for important information relating to clinical use, contraindications, serious warnings and precautions, adverse reactions, drug interactions, and dosage and administration that has not been discussed in this piece.

The Product Monograph is also available by calling us at 1-800-567-3331.

**Reference:** INVOKANA® Product Monograph. Janssen Inc. January 23, 2020.

**Pr** **Invokana**<sup>®</sup>  
canagliflozin tablets

**Janssen Inc.** 19 Green Belt Drive | Toronto, Ontario | M3C 1L9 | [www.janssen.com/canada](http://www.janssen.com/canada)

© 2020 Janssen Inc. | All trademarks used under license. | CP-129821E

 MEMBER OF  
INNOVATIVE MEDICINES CANADA

 PAAB

**janssen**  
PHARMACEUTICAL COMPANIES OF  
*Johansen-Johnson*

